Table 2.
Incidences of aortic aneurysm and dissection and other characteristics during the 10-year follow-up period
| Sjögren ’s syndrome | Total | With | Without | P values |
| N (%) | N (%) | N (%) | ||
| Total | 54 705 | 10 941 (20.00) | 43 764 (80.00) | |
| Aortic aneurysm and dissection | 207 (0.38) | 47 (0.43) | 160 (0.37) | 0.045 |
| Sex | 0.999 | |||
| Male | 10 187 (18.63) | 2011 (18.44) | 8176 (18.68) | |
| Female | 44 485 (81.37) | 8897 (81.56) | 35 588 (81.32) | |
| Age (years) | 61.36±5.41 | 60.90±4.98 | 61.47±5.51 | <0.001 |
| DM | 7603 (13.90) | 846 (7.73) | 6757 (15.44) | <0.001 |
| Hypertension | 8821 (16.12) | 1708 (15.61) | 7113 (16.25) | 0.102 |
| Hyperlipidaemia | 1128 (2.06) | 240 (2.19) | 888 (2.03) | 0.279 |
| Behcet’s disease | 324 (0.59) | 63 (0.58) | 261 (0.60) | 0.802 |
| Giant cell arteritis | 16 (0.03) | 3 (0.03) | 13 (0.03) | 0.901 |
| Rheumatoid arthritis | 9033 (16.51) | 1774 (16.21) | 7259 (16.59) | 0.348 |
| Relapsing polychondritis | 80 (0.15) | 19 (0.17) | 61 (0.14) | 0.401 |
| Takayasu’s arteritis | 15 (0.03%) | 3 (0.03) | 12 (0.03) | 0.999 |
| COPD | 3593 (6.57) | 652 (5.96) | 2941 (6.72) | 0.004 |
| CCI_R | 0.78±1.53 | 0.83±1.39 | 0.77±1.56 | <0.001 |
| Steroid | 17 112 (31.28) | 3511 (32.09) | 13 601 (31.08) | 0.041 |
| β Blockers | 13 750 (25.13) | 2674 (24.44) | 11 076 (25.31) | 0.061 |
| CCB | 11 833 (21.63) | 2397 (21.91) | 9436 (21.56) | 0.430 |
| ACEI | 13 793 (25.21) | 2784 (25.45) | 11 009 (25.16) | 0.532 |
| ARB | 12 976 (23.72) | 2681 (24.50) | 10 295 (23.52) | 0.031 |
| Diuretic | 12 692 (23.20) | 2507 (22.91) | 10 185 (23.27) | 0.427 |
| Statin | 14 123 (25.82) | 2828 (25.85) | 11 295 (25.81) | 0.934 |
P value (categorical variable: χ2/Fisher’s exact test; continuous variable: t-test).
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CCI_R, Charlson Comorbidity Index removed; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.